We are thrilled to share that our CRISPR-Chip™, the backbone of our CRISPR Analytics Platform™, is now being showcased at the German DHMD museum in Dresden as part of the esteemed exhibition ‘Of Genes and Human Beings.’ Seeing our innovative technology displayed alongside Watson and Crick’s DNA model is truly an honor and a testament […]
Read Original Article Here CRISPR QC™ announced the formation of its Scientific Advisory Board with the appointment of three distinguished members, Dr. Rodolphe Barrangou, Dr. Gene Dantsker, and Dr. Jared Carlson-Stevermer. Dr. Kiana Aran will be leading the advisory board. “I am excited to join the Scientific Advisory Board of CRISPR QC™ and contribute to […]
Read Full Article Here CRISPR QC™ is proud to announce that co-founder Kiana Aran has been recognized by Inc. magazine as a top 200 Female Founder. This prestigious list highlights women entrepreneurs who are making a significant impact in their respective industries and driving change. “As a female founder, I hope to inspire other women […]
With $1.6 million of seed funding recently added to its balance sheet, CRISPR QC™ is advancing the commercial development of its data analytics platform for gene editing. READ FULL ARTICLE HERE The San Diego-based startup currently offers an in vitro CRISPR-based assay as a service to help customers gain insights into the performance of their […]
CRISPR QC™ has announced that they have closed their Seed Round at $1.6M and appointed George Bonaros to the Board of Directors to fuel the commercial growth of their CRISPR Analytics Platform™. The round was led by Serra Ventures. READ FULL ARTICLE HERE CRISPR QC’s CRISPR Analytics Platform provides new dimensions of data and analytics […]
READ FULL ARTICLE HERE By Kiana Aran, PhD The adoption of CRISPR-Cas systems in therapeutics development has led to the rapid emergence of several clinical candidates for treating rare and challenging diseases, including sickle-cell anemia, β-thalassemia, Duchenne muscular dystrophy, and ocular diseases. Translation into the clinic has been facilitated by a robust preclinical framework of […]
CRISPR QC™ has announced that Toby Richardson, PhD has been appointed to the board of directors. READ FULL ARTICLE HERE CRISPR QC™ has already started proving that the unique capabilities of our CRISPR Analytics Platform™ can interrogate previously unknowable dimensions of gene editing that is translating into real value for our customers, says Ross Bundy, […]
Technology Driven Insights to Improve CRISPR Edit Outcomes READ THE FULL ARTICLE HERE SAN DIEGO–(BUSINESS WIRE)–On August 12, 2022, EvoNexus, California’s leading non-profit tech incubator, selected CRISPR QC™ to become a portfolio company. “Since 2010, EvoNexus portfolio companies have raised over $1.7B with 40 exits totaling over $2.1B” “The right environment and mentorship is critical […]
Dr. Kiana Aran, co-founder of CRISPR QC™, is featured as a guest on the DNA Today podcast. View the interview below. Associate Professor of Medical Diagnostics and Therapeutics and head of the Aran Lab at Keck Graduate Institute (KGI) where she works to develop CRISPR Quality Control standards. Dr. Aran is also the Chief Scientific […]
Technology Driven Insights to Improve CRISPR Edit Outcomes READ THE FULL ARTICLE HERE June 09, 2022, 01:04 PM Eastern Daylight Time SAN DIEGO–(BUSINESS WIRE)–On June 09, 2022, CRISPR QC™ has announced that Paul Grint and Dr. Kiana Aran have been appointed to the board of directors. “CRISPR QC’s technology is empowering scientists to put the […]
